Soft tissue sarcomas (STSs) are a rare and fascinating group of diseases that can be subdivided into specific reciprocal translocations in STSs (SRTSs) and nonspecific reciprocal translocations in STSs (NRTSs). PTEN mutations are rare in STSs, suggesting that PTEN expression may be lost by alternative mechanisms such as methylation. In order to reveal whether aberrant PTEN methylation occurs in STSs, MassARRAY Spectrometry was carried to detect methylation patterns of PTEN in STSs. We evaluated methylation levels in 41 CpG sites from ？2,515 to ？2,186 bp (amplicon A) and ？1,786 to ？1,416 bp (amplicon B) relative to the translation initiation site in 110 different cases (46 cases of SRTSs, 40 cases of NRTSs, and 24 cases of normal controls). In addition, immunohistochemistry (IHC) was used to detect the loss of PTEN to determine whether PTEN alterations were responsible for decreased PTEN expression. Our data showed that expression of PTEN was diminished in 49 (57%) STSs, whereas the remaining cases (43%) were classified as high expression. Our previous results found that only 2 of 86 cases (2.3%) had a PTEN mutation suggesting that PTEN may be mainly downregulated in STSs by methylation, but not by mutation of PTEN itself. We observed that amplicon A was hypermethylated in STSs with low PTEN expression, whereas normal controls had low methylation levels (P<0.0001), which was not present in amplicon B (P>0.05), nor were there significant differences in the methylation levels in PTEN between SRTS and NRTS cases. The majority of individual CpG units within two amplicons was demonstrated to be hypermethylated. These findings indicate that PTEN hypermethylation is a common event in STSs suggesting that the inactivation of PTEN may be due to hypermethylation in the promoter of PTEN. The aberrant methylation of the CpG sites within PTEN promoter may serve as a potential candidate biomarker for STSs.
References
[1]
Fletcher CDM, Unni KK, Mertens F, editors (2002) World Health Organization classification of tumors; pathology and genetics of tumors of soft tissue and bone. Lyon, France IARCPress.
[2]
Mertens F, Panagopoulos I, Mandahl N (2010) Genomic characteristics of soft tissue Sarcomas. Virchows Arch 456: 129–139.
[3]
Myers MP, Stolarov JP, Eng C, Li J, Wang SI, et al. (1997) PTEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci USA 94: 9052–9057.
[4]
Saito T, Oda Y, Kawaguchik T, Takahira T, Yamamoto H, et al. (2003) PTEN/MMAC1 gene mutation is a rare event in soft tissue sarcomas without specific balanced translocations. Int J Cancer 104: 175–178.
[5]
Zhu Y, Wang DY, Sugimura H (2001) Mutation analysis of tumor suppressor gene PTEN in bone and soft tissue tumors. Natl Med J China 81: 715–718.
[6]
Sjoling A, Samuelson E, Adamovic T, Behboudi A, R？hme D, et al. (2003) Recurrent allelic imbalance at the rat Pten locus in DMBA-induced fibrosarcomas. Genes Chromosomes Cancer 36: 70–79.
[7]
Yin L, Liu CX, Nong WX, Chen YZ, Qi Y, et al. (2012) Mutational analysis of p53 and PTEN in soft tissue sarcoma. Mol Med Report 5(2): 457–461.
[8]
Kawaguchi K, Oda Y, Saito T, Yamamoto H, Takahira T, et al. (2006) DNA hypermethylation status of multiple genes in soft tissue sarcomas. Modern Pathology 19: 106–114.
[9]
Kawaguchi K, Oda Y, Saito T, Takahira T, Yamamoto H, et al. (2005) Genetic and epigenetic alterations of the PTEN gene in soft tissue sarcoma. Human pathology 36: 357–363.
[10]
Joseph S, David WR (2001) Molecular cloning: a laboratory manual. 3rd ed. New York: Cold Spring Harbor Laboratory Press 461–485.
[11]
Soria JC, Lee HY, Lee JI, Wang L, Issa JP, et al. (2002) Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res 8: 1178–1184.
[12]
Furuta J, Umebayashi Y, Miyamoto K, Kikuchi K, Otsuka F, et al. (2004) Promoter methylation profiling of 30 genes in human malignant melanoma. Cancer Sci 95(12): 962–968.
[13]
Hino R, Uozaki H, Murakami N, Ushiku T, Shinozaki , et al. (2009) Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma. Cancer Res 69(7): 2766–2774.
[14]
Zysman MA, Chapman WB, Bapat B (2002) Considerations when analyzing the methylation status of PTEN tumor suppressor gene. Am J Pathol 160: 795–800.
[15]
Coolen MW, Statham AL, Gardiner-Garden M, Clark SJ (2007) Genomic profiling of CpG methylation and allelic specificity using quantitative highthroughput mass spectrometry: critical evaluation and improvements. Nucleic Acids Res 35(18): e119.
[16]
Olk-Batz C, Poetsch AR, N？llke P, Claus R, Zucknick M, et al. (2011) Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome. Blood 117(18): 4871–4880.
[17]
Kotilingam D, Lev DC, Lazar AJ, Pollock RE (2006) Staging soft tissue sarcoma: evolution and change. CA Cancer J Clin 56(5): 282–291.
[18]
Li J, Yen C, Liaw D, Podsypanina K, Bose S, et al. (1997) PTEN, a putative protein tyrosinephosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943–1947.
[19]
Li HG, Wang Q, Li HM, Kumar S, Parker C, et al. (2007) PAX3 and PAX3-FKHR promote rhabdomyosarcoma cell survival through downregulation o-f PTEN. Cancer Letters 253(2): 215–223.
[20]
Ehrich M, Field JK, Liloglou T, Xinarianos G, Oeth P, et al. (2006) Cytosine methylation profiles as a molecular marker in non-small cell lung cancer. Cancer Res 66(22): 10911–10918.
[21]
Radpour R, Haghighi MM, Fan AX, Torbati PM, Hahn S, et al. (2008) High-throughput hacking of the methylation patterns in breast cancer by in vitro transcription and thymidine-specific cleavage mass array on MALDI-TOF silico-chip. Mol Cancer Res 6(11): 1702–1709.
[22]
Vanaja DK, Ehrich M, Van den Boom D, Cheville JC, Karnes RJ, et al. (2009) Hypermethylation of Genes for Diagnosis and Risk Stratification of Prostate Cancer. Cancer Invest 27(5): 549–560.
[23]
Bullinger L, Ehrich M, Dohner K, Schlenk RF, D？hner H, et al. (2010) Quantitative DNA-methylation predicts survival in adult acute myeloid leukemia. Blood 115(3): 636–642.
